Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions

Journal of the American College of Cardiology

Volumn 30, Issue 5, 1997, Pages 1264-1269

  Shah, Pinak B ^a   Ahmed, Waqar H ^a   Ganz, Peter ^a   Bittl, John A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0030777899     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00274-X     Document Type: Article

References (47)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
2. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi role of platelet factor 4 . Circulation. 89:1994;1523-1529.
3. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety . Chest. 108:1995;258S-275S.
4. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 87:1993;1622-1629.
5. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial . Circulation. 92:1995;727-733.
6. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 333:1995;764-769.
7. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 5:1985;609-616.
8. Ahmed WH, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol. 72:1993;544-550.
9. Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina angiographic assessment and thrombolytic therapy during ongoing anginal attacks . Circulation. 77:1988;526-534.
10. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 315:1986;913-919.
11. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 326:1992;287-291.
12. Falk E. Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and/or sudden death . Circulation. 71:1985;699-708.
13. Davies MJ, Thomas AC. Plaque fissuring the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina . Br Heart J. 53:1985;363-373.
14. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering ischemic cardiac death. Circulation. 73:1986;418-427.
15. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris. J Am Coll Cardiol. 24:1994;1195-1206.
16. Rehr R, Disciascio G, Vetrovec G, Cowley M. Angiographic morphology of coronary artery stenoses in prolonged rest angina evidence of intracoronary thrombosis . J Am Coll Cardiol. 14:1989;1429-1437.
17. Teirstein PS, Schatz RA, Denardo SJ, Jensen EE, Johnson AD. Angioscopic versus angiographic detection of thrombus during coronary interventional procedures. Am J Cardiol. 75:1995;1083-1087.
18. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 77:1988;1213-1220.
19. Tabata H, Mizuno K, Arakawa K, et al. Angioscopic identification of coronary thrombus in patients with postinfarction angina. J Am Coll Cardiol. 25:1995;1282-1285.
20. Wolfe MW, Roubin GS, Schweiger M, et al. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty clinical and procedural predictors . Circulation. 92:1995;311-319.
21. The prognostic importance of the electrocardiogram after myocardial infarction: experience in the Coronary Drug Project. Ann Intern Med. 77:1972;677-689.
22. Detre KM, Holmes DR Jr, Holubkov R, et al. Incidence and consequences of periprocedural occlusion the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry . Circulation. 82:1990;739-750.
23. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction TIMI II A results . JAMA. 260:1988;2849-2858.
24. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 85:1992;916-927.
25. Uehata A, Matsugushi T, Bittl JA, et al. Accuracy of electronic digital calipers compared with quantitative angiography in measuring arterial diameter. Circulation. 88:1993;1724-1729.
26. Vetrovec GW, Leinbach RC, Gold HK, Cowley MJ. Intracoronary thrombolysis in syndromes of unstable ischemia angiographic and clinical results . Am Heart J. 104:1982;946-952.
27. Rosner B. Regression and correlation methods. Rosner B. Fundamentals of Biostatistics. 3rd ed. 1990;455-458 PWS-Kent, Boston.
28. Zar JH. Biostatistical Analysis. 2nd ed. 1984;122-149 Prentice-Hall, Englewood Cliffs (NJ).
29. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina relation to timing of angiography and in-hospital cardiac events . Circulation. 80:1989;17-23.
30. Ellis SG, Roubin GS, King SB III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation. 77:1988;372-379.
31. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA risk angioscopy as a clinical tool . Circulation. 93:1996;253-258.
32. Mabin TA, Holmes DR, Smith HC, et al. Intracoronary thrombus role in coronary occlusion complicating percutaneous transluminal coronary angioplasty . J Am Coll Cardiol. 5:1985;198-202.
33. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty current experience and analysis . J Am Coll Cardiol. 19:1992;1641-1652.
34. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
35. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial . J Am Coll Cardiol. 23:1994;993-1003.
36. Davies MJ. Thrombosis and coronary atherosclerosis. Julian D, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M. Thrombolysis in Cardiovascular Disease. 1989;25-43 Marcel Dekker, New York.
37. Ambrose JA. Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different? J Am Coll Cardiol. 19:1992;1653-1658.
38. Rosenberg RD, Bauer KA. The heparin-antithrombin system a natural anticoagulant mechanism . Colman RW, Hirsh J, Marder VJ, Salzman EW. Hemostasis and Thrombosis Basic Principles and Clinical Practice . 3rd ed. 1994;837-860 J.B. Lippincott, Philadelphia.
39. Zoldheyi P, Janssens S, Lefèvere G, Collen D, Van de Werf F, for the GUSTO-2a Investigators. Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction [abstract]. Circulation 1995;92 Suppl I:I-740.
40. Rao AK, Sun L, Chesebro JH, et al. Distinct effects of recombinant desulfatohirudin CGP 39,393 and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1. 2 in unstable angina a multicenter trial [abstract]. Thromb Haemost . 73:1995;1306.
41. Gallistl S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost. 74:1995;1163-1168.
42. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous coronary transluminal angioplasty outcome in patients with coronary arterial thrombosis. Am J Cardiol. 65:1990;179-182.
43. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.
44. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
45. Serruys PW, Herrman JR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 333:1995;757-763.
46. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
47. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis results at six months . Lancet. 343:1994;881-886.